Injeção de vírus interrompe o crescimento de tumor pancreático em estudo

29 de maio de 2026

Reportado por IA

Um vírus geneticamente modificado impediu o crescimento de tumores pancreáticos em três pacientes durante um estudo clínico inicial nos EUA. Os resultados provêm de uma pesquisa de segurança conduzida por pesquisadores da Universidade de Minnesota.

O primeiro paciente recebeu o tratamento há um ano após o diagnóstico de um tumor de 7 centímetros confinado ao pâncreas. Os outros dois pacientes foram tratados posteriormente, e todos os três permanecem vivos com a doença estável, segundo Masato Yamamoto, que liderou o desenvolvimento da terapia. Apenas um décimo da dose planejada foi utilizado nesta fase inicial, contudo, os tumores não se espalharam nem aumentaram de tamanho desde a injeção.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

05 de junho de 2026 Reportado por IA Imagem gerada por IA Verificado

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Sugar-coated nanoparticles boost glioblastoma survival in mice

17 de julho de 2026 Reportado por IA

Researchers at Oregon State University have developed an experimental treatment that uses sugar-coated nanoparticles to deliver genetic material across the blood-brain barrier in a mouse model of glioblastoma. The approach restored a tumor-suppressing protein and increased median survival by 50 percent while shrinking tumors without measurable organ toxicity.

Health

Experimental mRNA vaccine shows protection against multiple ebola viruses

Health

FDA-approved drug shows promise against rare liver cancer

Health

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers

Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.

USC scientists create renewable supply of cancer-fighting cells

29 de junho de 2026 Reportado por IA

Researchers at USC Stem Cell have developed a method to produce large numbers of immune cell precursors that can be engineered to target cancer. The approach, published in the journal Cell, uses granulocyte-monocyte progenitors that self-renew in the laboratory.

Gene-editing drug slashes bad cholesterol 62 percent in trial

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

terça-feira, 21 de julho de 2026, 20:27h